Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus

T. Petrasek, I. Vojtechova, O. Klovrza, K. Tuckova, C. Vejmola, J. Rak, A. Sulakova, D. Kaping, N. Bernhardt, PJ. de Vries, J. Otahal, R. Waltereit

. 2021 ; 13 (1) : 14. [pub] 20210417

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21025845

BACKGROUND: Tuberous sclerosis complex (TSC), a multi-system genetic disorder often associated with autism spectrum disorder (ASD), is caused by mutations of TSC1 or TSC2, which lead to constitutive overactivation of mammalian target of rapamycin (mTOR). In several Tsc1+/- and Tsc2+/- animal models, cognitive and social behavior deficits were reversed by mTOR inhibitors. However, phase II studies have not shown amelioration of ASD and cognitive deficits in individuals with TSC during mTOR inhibitor therapy. We asked here if developmental epilepsy, common in the majority of individuals with TSC but absent in most animal models, could explain the discrepancy. METHODS: At postnatal day P12, developmental status epilepticus (DSE) was induced in male Tsc2+/- (Eker) and wild-type rats, establishing four experimental groups including controls. In adult animals (n = 36), the behavior was assessed in the paradigms of social interaction test, elevated plus-maze, light-dark test, Y-maze, and novel object recognition. The testing was carried out before medication (T1), during a 2-week treatment with the mTOR inhibitor everolimus (T2) and after an 8-week washing-out (T3). Electroencephalographic (EEG) activity was recorded in a separate set of animals (n = 18). RESULTS: Both Tsc2+/- mutation and DSE caused social behavior deficits and epileptiform EEG abnormalities (T1). Everolimus led to a persistent improvement of the social deficit induced by Tsc2+/-, while deficits related to DSE did not respond to everolimus (T2, T3). CONCLUSIONS: These findings may contribute to an explanation why ASD symptoms in individuals with TSC, where comorbid early-onset epilepsy is common, were not reliably ameliorated by mTOR inhibitors in clinical studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21025845
003      
CZ-PrNML
005      
20211026133441.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s11689-021-09357-2 $2 doi
035    __
$a (PubMed)33863288
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Petrasek, Tomas $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic. tomas.petrasek@nudz.cz
245    10
$a mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus / $c T. Petrasek, I. Vojtechova, O. Klovrza, K. Tuckova, C. Vejmola, J. Rak, A. Sulakova, D. Kaping, N. Bernhardt, PJ. de Vries, J. Otahal, R. Waltereit
520    9_
$a BACKGROUND: Tuberous sclerosis complex (TSC), a multi-system genetic disorder often associated with autism spectrum disorder (ASD), is caused by mutations of TSC1 or TSC2, which lead to constitutive overactivation of mammalian target of rapamycin (mTOR). In several Tsc1+/- and Tsc2+/- animal models, cognitive and social behavior deficits were reversed by mTOR inhibitors. However, phase II studies have not shown amelioration of ASD and cognitive deficits in individuals with TSC during mTOR inhibitor therapy. We asked here if developmental epilepsy, common in the majority of individuals with TSC but absent in most animal models, could explain the discrepancy. METHODS: At postnatal day P12, developmental status epilepticus (DSE) was induced in male Tsc2+/- (Eker) and wild-type rats, establishing four experimental groups including controls. In adult animals (n = 36), the behavior was assessed in the paradigms of social interaction test, elevated plus-maze, light-dark test, Y-maze, and novel object recognition. The testing was carried out before medication (T1), during a 2-week treatment with the mTOR inhibitor everolimus (T2) and after an 8-week washing-out (T3). Electroencephalographic (EEG) activity was recorded in a separate set of animals (n = 18). RESULTS: Both Tsc2+/- mutation and DSE caused social behavior deficits and epileptiform EEG abnormalities (T1). Everolimus led to a persistent improvement of the social deficit induced by Tsc2+/-, while deficits related to DSE did not respond to everolimus (T2, T3). CONCLUSIONS: These findings may contribute to an explanation why ASD symptoms in individuals with TSC, where comorbid early-onset epilepsy is common, were not reliably ameliorated by mTOR inhibitors in clinical studies.
650    _2
$a zvířata $7 D000818
650    12
$a autistická porucha $7 D001321
650    _2
$a haploinsuficience $7 D057895
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a krysa rodu Rattus $7 D051381
650    12
$a status epilepticus $7 D013226
650    _2
$a TOR serin-threoninkinasy $x genetika $7 D058570
650    _2
$a tuberin $x genetika $7 D000077005
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vojtechova, Iveta $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic $u First Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Klovrza, Ondrej $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic $u Second Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Tuckova, Klara $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic $u Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Vejmola, Cestmir $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Rak, Jakub $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Sulakova, Anna $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Kaping, Daniel $u National Institute of Mental Health, Topolova 748, 250 67, Klecany, Czech Republic
700    1_
$a Bernhardt, Nadine $u Department of Psychiatry, University Hospital and Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany
700    1_
$a de Vries, Petrus J $u Division of Child & Adolescent Psychiatry, University of Cape Town, Cape Town, South Africa
700    1_
$a Otahal, Jakub $u Department of Developmental Epileptology, Institute of Physiology CAS, Prague, Czech Republic
700    1_
$a Waltereit, Robert $u Department of Child and Adolescent Psychiatry, University Hospital and Medical Faculty Carl Gustav Carus, Technical University of Dresden, Dresden, Germany. robert.waltereit@med.uni-goettingen.de $u Department of Child and Adolescent Psychiatry, University Medical Center Göttingen, Von-Siebold-Str. 5, 37075, Göttingen, Germany. robert.waltereit@med.uni-goettingen.de
773    0_
$w MED00189539 $t Journal of neurodevelopmental disorders $x 1866-1955 $g Roč. 13, č. 1 (2021), s. 14
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33863288 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133447 $b ABA008
999    __
$a ok $b bmc $g 1714757 $s 1146352
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 13 $c 1 $d 14 $e 20210417 $i 1866-1955 $m Journal of neurodevelopmental disorders $n J Neurodev Disord $x MED00189539
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace